Scientific research will highlight advances in dry powder inhaler (DPI) platform products, patient-centric design and ...

Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. The Food and Drug Administration (FDA) has approved ...

Dry powder inhalers (DPIs) have become a mainstay in the management of chronic pulmonary diseases such as chronic obstructive pulmonary disease and asthma. Their performance depends on a complex ...

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...

Mannkind and United Therapeutics are creating an inhaled formulation of ralinepag, an experimental oral PAH treatment.

An inhaler is a device that helps you breathe medication directly into your lungs. People typically use inhalers to treat asthma or chronic obstructive pulmonary disease (COPD). Many people find DPIs ...

Pulmonary administration exploits the large surface area and thin epithelial barrier of the lung to achieve both local and systemic therapy with rapid onset. Delivery platforms include nebulisers, ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...